Journey Clinical’s Post

Journey Clinical was featured in Forbes for our research collaboration with Compass Pathways to inform how COMP360 psilocybin treatment may be delivered to patients with treatment-resistant depression across the US, if approved. “With a network of more than 2,000 therapists and a comprehensive training and education program, Journey Clinical has the infrastructure to support broad access to innovative psychedelic treatments for mental health conditions.” Pioneering mental health treatments, like investigational COMP360 psilocybin therapy, are showing promise in providing relief to those suffering from treatment-resistant depression (TRD). In the article, Steve Levine, MD, SVP of Patient Access and Medical Affairs at Compass Pathways, highlighted Journey Clinical’s research collaboration aimed at developing a scalable delivery and training model for COMP360 psilocybin treatment. Our partnership with Compass Pathways is a testament to Journey Clinical’s mission to transform the mental health landscape by empowering licensed psychotherapists to deliver evidence-based Psychedelic-Assisted Psychotherapy safely and effectively. Learn more about this research collaboration: https://lnkd.in/gP3u5WvV

Collaborative care is at the heart of Journey Clinical. Journey Clinical Lead Clinician, Brigitte Gordon, DNP, PMHNP-BC, spoke about our patient-centered collaborative care model at last month’s Fluence X Journey Clinical community event. Within our model, Journey Clinical’s highly trained, in-house medical team partners with licensed psychotherapists in our network to deliver the highest quality of care to our shared patients. During the event, Brigitte spoke about the sensitivity and care that goes into all medical responsibilities of Ketamine-Assisted Psychotherapy to ensure that each patient receives a tailored experience. If you’re a licensed mental health professional looking to begin your own Ketamine-Assisted Psychotherapy (KAP) practice with Journey Clinical, or a potential patient interested in learning more about KAP treatment, visit: https://lnkd.in/egp42SXM

“These attributes potentially improve the scalability of ketamine use in the community, due to reduced need for in-clinic monitoring, and would also reduce costs associated with clinic visits.” Writer Anuradha Varanasi recently reported on the findings of a clinical trial testing ketamine tablets as a treatment for treatment-resistant depression. Varanasi notes: “The team observed that while 71% of the patients in the placebo group experienced a relapse of a depressive episode, in the group of patients who took 180 mg of ketamine tablets as prescribed, only 43% of patients reported a relapse.” To learn more about whether Ketamine-Assisted Psychotherapy (KAP) treatment would be a good fit for you, please visit: https://bit.ly/3Laycpw

According to the APA, 45% of adults ages 35 to 44 reported living with mental illness in 2023 – skyrocketing from 31% in 2019. At Journey Clinical, we believe Ketamine-Assisted Psychotherapy can be a powerful tool to help patients create lasting change, break free from old thought patterns, and embrace new perspectives. Psychotherapy with a trusted clinician is a key component of the treatment process. If you’re a licensed mental health professional looking to begin your own Ketamine-Assisted Psychotherapy (KAP) practice with Journey Clinical, or a prospective patient interested in learning more about KAP treatment, visit: https://lnkd.in/egp42SXM

Thank you, Yamil S. for spreading the word! NYC Ketamine-Assisted Psychotherapists (and those interested in learning more about psychedelic therapy) - join us and Juanita Viera, LCAT tonight for an evening of discovery and connection, featuring a sound bath and art-making experience. We hope to see you there! RSVP here: https://lnkd.in/ewnSuFrw

“My mind was just completely blown because a lot of my clients struggle so much, and some of them have struggled for decades. To hear that there was treatment available that was showing such quick improvements, I just knew that I wanted to be a part of that.” We sat down with Journey Clinical KAP Provider, Sonia Albin, LPC, to discuss the patient outcomes she has seen since integrating Ketamine-Assisted Psychotherapy in her practice. Sonia is the founder of Kite Ecotherapy, and her work focuses mainly on treatment of complex trauma and eating disorders. Thank you, Sonia, for the incredible work you are doing! Learn more about Sonia’s practice in our latest Community Feature here: https://lnkd.in/eUzazvjQ

Journey Clinical KAP Provider L.J. Lumpkin III, LMFT shared with us the incredible transformation of one of his patients, who had served a collective 20 years in both the Marines and law enforcement, thanks to Ketamine-Assisted Psychotherapy. Thank you, LJ, for sharing this story that highlights the incredible outcomes KAP can provide for Veterans or patients in law enforcement! If you’re a licensed mental health professional looking to begin your own KAP practice with Journey Clinical, or a potential patient interested in learning more about KAP treatment, visit https://bit.ly/3BtzvMg